Close Menu

NEW YORK (360Dx) – A team led by scientists at Stanford University has engineered immune cells to serve as cancer diagnostics.

In a study published this week in Nature Biotechnology, the researchers demonstrated the ability of engineered macrophages to detect tumors as small as 25 mm3 and with sensitivity superior to that offered by endogenous protein or nucleic acid biomarkers.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.
Sponsored by

Join Dr. Heather Fehling, Chief Scientific Officer at Clinical Reference Labs (CRL), as she provides some insights regarding the future applications of PCR testing.